Churchill Downs Inc: 1 director

A director at Churchill Downs Inc bought 3,800 shares at 130.220USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Worldline : Début d’année apportant du crédit aux objectifs 2024

>Croissance organique faible au T1 mais au-dessus des attentes - Worldline vient de publier son CA au titre du T1 2024. Il fait ressortir une croissance organique faible à +2.5% mais au-dessus des attentes (ODDO BHF / consensus = +1.2/+0.7%) et en amélioration par rapport au point bas du T4 2023 (+1.3%).Les Services aux Commerçants s’avèrent plus dynamique que prévu (+3.9% dont +6.5% hors arrêt planifié de commerçants – rappel T4 2023 = +3.2%) grâce à de bons rés...

adidas: The best sunny terrace in sporting goods currently...

During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We

Higher guidance, 15% beat on Q1 EBIT

GALP : Résultats T1 supérieurs aux attentes, outlook rassurant. Recomm...

>Upstream : un profil de croissance solide renforcé par les découvertes en Namibie - L’EBITDA T1 2024 ajusté de l’Upstream est ressorti à 591 M€ et 9% au-dessus des attentes. Le groupe guide sur un EBITDA 2024 de la division à 2.1 Md€ qui nous parait assez conservateur et une production >115 kbep/j en ligne avec nos attentes. Cette production devrait croitre de de plus de 30% (+40 kbep/j) avec le démarrage de Bacalhau au Brésil fin 2025 qui devrait atteindre son pl...

Mercedes-Benz AG : Continued erosion and risks still underestimated

>Continued erosion of Cars fundamentals - MBG reported subdued Q1 results Tuesday morning, below expectations (adjusted EBIT 5% below consensus, -10% for the Cars division), see First Take. The group reported a marked erosion of its earnings and margins in the Cars division (adjusted EBIT € 2.3bn, -44% y-o-y, margin 9.0%, -580bp y-o-y), partly offset by a still very solid performance from Vans (adjusted EBIT € 0.8bn, +11% y-o-y, margin 16.3%, -20bp y-o-y). The group ...

Savencia SA : Globalement l’amélioration du mix volume compense la bai...

>Un CA T1 stable en organique dont +1.7% de mix volume selon nos calculs. - Du contact société post publication du CA T1 (1696 M€, en hausse de 1.6% en publié et stable en organique), nous retenons les éléments suivants : La croissance organique des produits fromagers de 2.5% s’appuie sur un effet mix volume de 1% et une légère hausse des prix de 1.5%. Le groupe bénéficie des relèvements de prix obtenus en 2023 et ceux obtenus cette année sur certains marchés com...

GSK : Very good start to the year

>Q1 beat expectations - GSK reported Q1 sales (+4.4% vs consensus) and core EPS (+15.9% vs consensus) ahead of expectations. Sales were up 10% at cc (+6% GBP). All divisions turned in a good performance: Specialty Medicines (+12.8%, +1% vs css), Vaccines (+11.6%, +5.5% vs consensus) driven by Arexvy (£ 180m - launched in Q3 2023, in line) and Shingrix (+13.4%, +4.4% vs consensus) General Medicine declined less sharply than expected (-4.4%, +7.7% vs consensus). Core EB...

WOOD Flash – Alkaloid: 1Q24 numbers a strong start to the year

Alkaloid reported another solid set of results in 1Q24, albeit with the yoy comparison on some lines coloured by the reclassification of cost from below to above the operating line. This quarter, the business caught a tailwind from cephalosporin antibiotic sales in Ukraine (the first quarter is typically strong for all antibiotics), but also from recent investments in its Western European markets. Keeping in mind seasonality, the company is well on track to meet its FY24E revenues growth target ...

Cherry SE : Turnaround promised, but the proof will be in the pudding

>2023 another year to forget, but management optimistic about the future - Last year (2023) was again disappointing for Cherry, with it missing initial guidance by a mile on both revenue (€ 126.5m vs c. € 140m guidance, down 4.5% y-o-y) and adjusted EBITDA margin (1.6% vs guidance of c. 10%). The poor 2023 results were due to a mix of internal and external factors. First, management was running a business with a lack of focus (very diversified product portfolio), no d...

Fielmann AG : Activité un peu plus dynamique qu’attendu, guidance en m...

>Le CA T1 reflète une croissance plus favorable que prévu à +11% mais les marges restent du même ordre de grandeur que l’an passé sur le trimestre - Le groupe publie en même temps les résultats annuels 2023 complets (les principales données avaient déjà été communiquées le 29 février) et ceux afférents au T1 2024.  Le CA 2023 est confirmé à 1969 M€ soit une croissance de 12% et c.8% en organique (CA T4 à 7% soit quasi flat en org avec une Allemagne à -3.5%), l’EBT ...

BWP Trust: Update following outlook change to negative

Our credit view of this issuer reflects its strong primary tenant and conservative financial policy, against its weaker leverage and refinancing risk following the acquisition of NPR.

DSM-Firmenich FIRST LOOK :1Q adj EBITDA -11%, FY guidance maintained

1Q adj EBITDA decreased by 11% which was close to our and consensus forecasts. Dsm-firmenich expects to see higher vitamin prices as from 2Q and reiterated FY guidance of at least € 1.9bn adjusted EBITDA, with our and consensus forecasts close to € 2bn. The carve out of Animal Nutrition & Health has started and based on a gradual improvement of market conditions as well as earnings support from the € 200m vitamin restructuring program, we believe proceeds of € 3.0-3.5bn for ANH to be possible, w...